Literature DB >> 19551837

Genetic characterization of Chinese measles vaccines by analysis of complete genomic sequences.

Yan Zhang1, Jianhui Zhou, William J Bellini, Wenbo Xu, Paul A Rota.   

Abstract

The complete genomic sequences of two Chinese measles vaccine viruses, Shanghai-191 (S-191) and Changchun-47 (C-47), were determined and compared to the sequences of other measles vaccine strains as well as the prototype measles strain, Edmonston wild-type (Edwt). Compared to Edwt, S-191 and C-47 had 49 and 43 nucleotide changes, respectively. These differences were found at 52 nucleotide positions that were not found in other vaccine strains. Phylogenetic analysis of the all of the available genomic sequences for measles vaccines showed that S-191 and C-47 were most closely related to the Leningrad-4 strain. S-191 and C-47 shared conserved vaccine virus-specific amino acid changes in the phosphoprotein (P), V, C, matrix (M), and hemagglutinin (H) that could represent important targets for future studies aimed at understanding the molecular basis of attenuation. In addition, S-191 and C-47 had several unique amino acid changes including 13 positions that differed from Edwt. This is the first comparison of the complete genomic sequences of Chinese measles vaccines to the sequences of other vaccine strains. 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19551837     DOI: 10.1002/jmv.21535

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  7 in total

1.  Genetic characterization of wild-type measles viruses isolated in China, 2006-2007.

Authors:  Yixin Ji; Songtao Xu; Yan Zhang; Zhen Zhu; Naiying Mao; Xiaohong Jiang; Chao Ma; Peishan Lu; Changyin Wang; Yong Liang; Huanying Zheng; Yang Liu; Defang Dai; Lei Zheng; Jianhui Zhou; Shuang Wang; Zhenying Zhang; Shengwei Wu; Lijuan Nan; Li Li; Xiaofeng Liang; David Alexander Featherstone; Paul A Rota; William J Bellini; Wenbo Xu
Journal:  Virol J       Date:  2010-05-25       Impact factor: 4.099

2.  PACT- and RIG-I-Dependent Activation of Type I Interferon Production by a Defective Interfering RNA Derived from Measles Virus Vaccine.

Authors:  Ting-Hin Ho; Chun Kew; Pak-Yin Lui; Chi-Ping Chan; Takashi Satoh; Shizuo Akira; Dong-Yan Jin; Kin-Hang Kok
Journal:  J Virol       Date:  2015-11-25       Impact factor: 5.103

3.  Enhancement of safety and immunogenicity of the Chinese Hu191 measles virus vaccine by alteration of the S-adenosylmethionine (SAM) binding site in the large polymerase protein.

Authors:  Yilong Wang; Rongxian Liu; Mijia Lu; Yingzhi Yang; Duo Zhou; Xiaoqiang Hao; Dongming Zhou; Bin Wang; Jianrong Li; Yao-Wei Huang; Zhengyan Zhao
Journal:  Virology       Date:  2018-03-15       Impact factor: 3.616

4.  Phylogenetic and Epidemiological Analysis of Measles Viruses in Shenzhen, China from January 2015 to July 2019.

Authors:  Min Lei; Kai Wang; Jing Li; Yan Zhang; Xuemei Wei; Lifeng Qi; Gaofeng Zhou; Yue Wu
Journal:  Med Sci Monit       Date:  2019-12-04

5.  Measles Vaccine-Associated Rash Illness in China: an Emerging Issue in the Process of Measles Elimination.

Authors:  Aili Cui; Huiling Wang; Zhen Zhu; Naiying Mao; Jinhua Song; Yan Zhang; Wenbo Xu
Journal:  J Clin Microbiol       Date:  2020-10-21       Impact factor: 5.948

6.  Evolutionary genetics of genotype H1 measles viruses in China from 1993 to 2012.

Authors:  Songtao Xu; Yan Zhang; Pierre Rivailler; Huiling Wang; Yixin Ji; Zhu Zhen; Naiying Mao; Chongshan Li; William J Bellini; Wenbo Xu; Paul A Rota
Journal:  J Gen Virol       Date:  2014-06-09       Impact factor: 3.891

7.  Synergism of rMV-Hu191 with cisplatin to treat gastric cancer by acid sphingomyelinase-mediated apoptosis requiring integrity of lipid raft microdomains.

Authors:  Yao Lv; Chu-di Zhang; Yi-Long Wang; Dong-Ming Zhou; Meng-Ying Zhu; Xiao-Qiang Hao; Jin-Hu Wang; Wei-Zhong Gu; Hong-Qiang Shen; Jin-Gan Lou; Ben-Qing Wu; Pei-Chun Chen; Zheng-Yan Zhao
Journal:  Gastric Cancer       Date:  2021-07-12       Impact factor: 7.701

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.